scholarly journals The Synthesis and Evaluation of RGD−Conjugated Chitosan Gel as Daily Supplement for Body Weight Control

Materials ◽  
2021 ◽  
Vol 14 (16) ◽  
pp. 4467
Author(s):  
Wei-Yao Chen ◽  
Yu-Ting Chen ◽  
Cherng-Jyh Ke ◽  
Ching-Yun Chen ◽  
Feng-Huei Lin
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Chronic Diseases ◽  
Weight Control ◽  
Rgd Peptide ◽  
Health Food ◽  
Short Term ◽  
Body Weight Control

(1) Background: Obesity is one of the most widespread chronic diseases and increases the risk of several other chronic diseases, especially type 2 diabetes. (2) Methods: Endobarrier is a new medical device what is worn in the small intestines for the treatment of type 2 diabetes and obesity. However, given the invasive and other adverse effects of the Endobarrier, we propose the use of RGD peptide conjugated with chitosan (RC) as an alternative. (3) Results: The FTIR and NMR spectrum showed RGD peptide was successfully conjugated on chitosan and RGD−CT is retained in the small intestine even after digestion. In vitro of wst-1 and live and dead staining studies show that the RGD−CT gel is highly biocompatible and non-toxic. Rats treated with the RGD−CT gel for a short term showed significant decrease change more than 30% in body weight, while the blood and hematic biometrics were within normal values. (4) Conclusions: The RGD−CT gel is safe, suitable for the short-term, reducing visceral fat rate health food to control weight. In the future, it is expected to develop a safe, long-term effective, flexibility of use and low-side-effect anti-obesity therapy in the era of precision medicine by further modification.

scholarly journals A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes

2019 ◽  
Vol 10 (2) ◽  
pp. 683-696
Author(s):  
Cheli Melzer-Cohen ◽  
Gabriel Chodick ◽  
Lise Lotte N. Husemoen ◽  
Nicolai Rhee ◽  
Varda Shalev ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Database Study ◽  
Body Weight Control ◽  
Retrospective Database

scholarly journals Efficacy and Safety of Semaglutide in Glycemic Control and Body Weight Management Among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide From Other GLP-1 Receptor Agonists

2021 ◽  
Author(s):  
Aki Okamoto ◽  
Hirohide Yokokawa ◽  
Tomoko Nagamine ◽  
Hiroshi Fukuda ◽  
Teruhiko Hisaoka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Weight Control ◽  
Efficacy And Safety ◽  
Albumin Creatinine Ratio ◽  
Body Weight Control

Abstract Background: Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs.Methods: This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide.Results: A total of 50 patients were registered: 21 men and 29 women, aged 51.3 years. Mean body mass index was 32.2 kg/m2, and serum C-peptide was 2.7mg/mL. After switching to semaglutide (n=43), HbA1c and body weight significantly decreased from 6.72 % to 6.22 % and from 86.5 kg to 82.7 kg, respectively. The same findings were observed in semaglutide-naïve patients (n=7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well, whereas serum creatinine did not change significantly. Conclusion: Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.

Persistence to Liraglutide Therapy Is Associated with Good Glycemic and Body Weight Control in Patients with Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2295-PUB
Author(s):  
CHELI MELZER COHEN ◽  
GABRIEL CHODICK ◽  
LISE LOTTE N. HUSEMOEN ◽  
NICOLAI RHEE ◽  
VARDA SHALEV ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Body Weight Control

scholarly journals Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists

2021 ◽  
Author(s):  
Aki Okamoto ◽  
Hirohide Yokokawa ◽  
Tomoko Nagamine ◽  
Hiroshi Fukuda ◽  
Teruhiko Hisaoka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Weight Control ◽  
Efficacy And Safety ◽  
Control Body ◽  
Body Weight Control

Abstract Purpose Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs. Methods This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide. Results A total of 50 patients were registered in the study. After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p < 0.01, p < 0.01), respectively. The same findings were observed in semaglutide-naïve patients (p = 0.04, p < 0.02) (n = 7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51). Conclusions Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.

How to Maintain a Healthy Body Weight

2006 ◽  
Vol 76 (4) ◽  
pp. 208-215 ◽  
Author(s):  
Astrup
Keyword(s):  
Physical Activity ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Body Weight ◽  
Glycemic Index ◽  
Dairy Products ◽  
Weight Control ◽  
Healthy Body Weight ◽  
Healthy Body

The epidemic of both obesity and type 2 diabetes is due to environmental factors, but the individuals developing the conditions possess a strong genetic predisposition. Observational surveys and intervention studies have shown that excess body fatness is the major environmental cause of type 2 diabetes, and that even a minor weight loss can prevent its development in high-risk subjects. Maintenance of a healthy body weight in susceptible individuals requires 45–60 minutes physical activity daily, a fat-reduced diet with plenty of fruit, vegetables, whole grain, and lean meat and dairy products, and moderate consumption of calorie containing beverages. The use of table values to predict the glycemic index of meals is of little – if any – value, and the role of a low-glycemic index diet for body weight control is controversial. The replacement of starchy carbohydrates with protein from lean meat and lean dairy products enhances satiety, and facilitate weight control. It is possible that dairy calcium also promotes weight loss, although the mechanism of action remains unclear. A weight loss of 5–10% can be induced in almost all obese patients providing treatment is offered by a professional team consisting of a physician and dieticians or nurses trained to focus on weight loss and maintenance. Whereas increasing daily physical activity and regular exercise does not significantly effect the rate of weight loss in the induction phase, it plays an important role in the weight maintenance phase due to an impact on daily energy expenditure and also to a direct enhancement of insulin sensitivity.

scholarly journals Body Weight Control by a High-Carbohydrate/Low-Fat Diet Slows the Progression of Diabetic Kidney Damage in an Obese, Hypertensive, Type 2 Diabetic Rat Model

2010 ◽  
Vol 2010 ◽  
pp. 1-11 ◽  
Author(s):  
Shuichi Ohtomo ◽  
Yuko Izuhara ◽  
Masaomi Nangaku ◽  
Takashi Dan ◽  
Sadayoshi Ito ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Control ◽  
Advanced Glycation ◽  
Low Fat ◽  
High Carbohydrate ◽  
Low Fat Diet ◽  
Body Weight Control ◽  
And Oxidative Stress ◽  
Type 2 Diabetic

Obesity is one of several factors implicated in the genesis of diabetic nephropathy (DN). Obese, hypertensive, type 2 diabetic rats SHR/NDmcr-cp were given, for 12 weeks, either a normal, middle-carbohydrate/middle-fat diet (MC/MF group) or a high-carbohydrate/low-fat diet (HC/LF group). Daily caloric intake was the same in both groups. Nevertheless, the HC/LF group gained less weight. Despite equivalent degrees of hypertension, hyperglycemia, hyperlipidemia, hyperinsulinemia, and even a poorer glycemic control, the HC/LF group had less severe renal histological abnormalities and a reduced intrarenal advanced glycation and oxidative stress. Mediators of the renoprotection, specifically linked to obesity and body weight control, include a reduced renal inflammation and TGF-beta expression, together with an enhanced level of adiponectin. Altogether, these data identify a specific role of body weight control by a high-carbohydrate/low-fat diet in the progression of DN. Body weight control thus impacts on local intrarenal advanced glycation and oxidative stress through inflammation and adiponectin levels.

Owning a Dog as a Determinant of Physical Activity and Metabolic Control in Patients With Type 1 and Type 2 Diabetes Mellitus

2019 ◽  
Author(s):  
Julia Riske ◽  
Martin Janert ◽  
Melanie Kahle-Stephan ◽  
Michael A. Nauck
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Control ◽  
Weight Control ◽  
Total Physical Activity ◽  
Dog Owners ◽  
Body Weight Control

Abstract Background/aims Physical activity is recommended for patients with type 1 (T1D) and type 2 diabetes (T2D). We wanted to assess whether owning a dog influences duration or intensity of physical activity and metabolic control of diabetes mellitus. Patients and methods 143 patients with T1D (age 50±16 y.; BMI 25.7±4.5 kg/m2, HbA1c 8.6±1.6%) and 303 with T2D (age 63±11 y., BMI 33.7±7.3 kg/m2, HbA1c 9.0±1.6%, 232 [76.6%] insulin-treated, 89±61 IU/d), respectively, participated. A standardized questionnaire assessed diabetes history and treatment, details regarding time spent (per week) and intensity (MET, metabolic equivalent of task) of physical activity (“walking the dog” and other activities), anthropometric (BMI) and laboratory measures. Results 31.5% of T1D 23.1% of T2D patients were dog owners. Dog owners with T1D and T2D diabetes spent 19.0±3.3 and 19.8±2.6 MET.h per week walking the dog, which represented 61.3±5.7 and 62.9±4.9% of their total physical activity. Participants not owning a dog compensated by performing significantly more other activities. Taken together, total physical activity was similar in dog owners with T1D (p=0.80), but higher in dog owners with T2D (30.1±2.8 vs. 18.6±1.4 MET.h per week in those not owning a dog; p=0.0001). Body-mass-index or HbA1c were not significantly different in either patients with T1D or T2D either owning a dog or not. Conclusions Owning a dog motivates to a significant amount of physical activity, but this was fully compensated for by other forms of physical activity in (younger) patients with T1D. Even the higher physical activity in dog owners with T2D did not result in improved glycaemic or body weight control.

scholarly journals Selected health behaviours of type 2 diabetes patients

2017 ◽  
Vol 127 (4) ◽  
pp. 155-158
Author(s):  
Wioletta Samolińska ◽  
Bożena Kiczorowska ◽  
Edyta Kowalczuk-Vasilev ◽  
Renata Klebaniuk ◽  
Ewelina Jakubczak
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Age Groups ◽  
Health Behaviours ◽  
Diet Therapy ◽  
Self Monitoring ◽  
Fat Deposits ◽  
Diabetes Patients

Abstract Introduction. Type 2 diabetes is a chronic disease with an epidemic character. Its prevalence is associated with lifestyle, many environmental factors, and genetic determinants. Implementation of diet therapy is the basis for treatment of the disease. Aim. The aim of the study was to assess health behaviours and differences in these behaviours in type 2 diabetes patients taking their age into consideration. Material and methods. The questionnaire survey was carried out among 120 subjects diagnosed with type 2 diabetes. The original questionnaire comprised questions on selected pro-health behaviours, e.g. prophylactic behaviour or self-monitoring in the disease. The statistical analysis was performed on 111 properly completed surveys. The respondents were divided into three age groups: subjects under 60 (n=24), between 60 and 75 (n=64), and over 75 years old (n=23). Results. Regardless of their age, the patients with type 2 diabetes indicated mainly arteriel hypertension as a coexisting complication. The basic element of patients’ self-monitoring was checking the blood pressure and glycaemia. Half of the patients declared body weight control, however, a majority were characterised by excessive body weight and abdominal fat deposits, irrespective of their age. Walking was the most popular form of physical activity chosen by the respondents. Regardless of their age, the type 2 diabetes patients exhibited similar readiness for self-education related to their disease. Conclusions. The surveyed respondents exhibited similar behaviours undertaken to keep healthy. The increase in the regularity of doctor appointments and in the use of pharmacotherapy was closely related to age of the respondents. The advanced age of the respondents had an impact on the regularity of foot inspection. Respondents over 75 years of age adhered to recommendations on the schedule of food and medicine intake, but used diet therapy less frequently.

Sign in / Sign up

Export Citation Format

Share Document